Atul Deodhara (Oregon Health & Science University, Portland, OR, USA) kindly discusses the phase III results of the oral JAK inhibitor, tofacitinib, in the treatment of adult patients with Ankylosing Spondylitis. His abstract entitled: ‘Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study’ (NCT03502616) was presented at the ACR Convergence 2020, 5-9 November 2020.
- What is the rationale for the use of JAK inhibitors in the treatment of ankylosing spondylitis (AS)? (0:16)
- Could you tell me a little about the aims, design and eligibility criteria for the Phase III clinical study you presented investigating tofacitinib in the treatment of AS? (1:40)
- What were the major efficacy findings from the primary analysis of this study? (2:56)
- What were the major safety findings? (3:58)
- What do you think will be the next steps in the clinical development of tofacitinib, and other JAK inhibitors, in the treatment of ankylosing spondylitis? (4:57)
Disclosures: Atul Deodhar has acted as a consultant/participated in advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Glaxo Smith & Kline, Janssen, Novartis, Pfizer and UCB. He has also received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Axial Spondyloarthritis
Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis
It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment. ‘NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA […]
Peter Taylor, EULAR 2021: Highlights from the Congress
We had the pleasure to meet with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) who gave us some of the key highlights from this year’s European Congress of Rheumatology meeting, 2-5 June 2021. Questions What were the highlights of this year’s EULAR meeting? (0:11) Disclosures: Peter C Taylor reports receiving: Research grants […]
Marina Magrey, ACR 2020 – Ixekizumab Response in Nr-axSpA Based on HLA-B27 and Disease Duration: The COAST-X Study
It was a pleasure to speak with Marina Magrey (Case Western Reserve University School of Medicine/ MetroHeath Medical Center, Cleveland, OH, USA) about the recent post-hoc analysis from the COAST X study (NCT02757352). The analysis was designed to evaluate the efficacy of ixekizumab at week 16 in patients with non-radiographic axial spondyloarthritis (nr-axSpA) with or […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!